Skip to main content
Log in

Clinical trials report

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:460–465.

    Google Scholar 

  2. Sato A, Saruta T: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients. J Int Med Res 2001, 29:13–21.

    PubMed  CAS  Google Scholar 

  3. Wambach G, Helber A, Bonner G, et al.: Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn’s syndrome. Deutsch Med Wochenschr 1980, 105:647–651.

    CAS  Google Scholar 

  4. Karlberg BE, Kagedal B, Tegler L, Kerstin T: Renin concentrations and effects of propranolol and spironolactone in patients with hypertension. BMJ 1976, 1:251–254.

    Article  PubMed  CAS  Google Scholar 

  5. Lim PO, Jung RT, MacDonald TM: Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002, 16:153–158.

    Article  PubMed  CAS  Google Scholar 

  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  7. The RALES Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.

    Article  Google Scholar 

  8. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001, 110:438–441.

    Article  PubMed  CAS  Google Scholar 

  9. Barzilay JI, Jones CL, Davis BR, et al.: Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001, 24:654–658.

    Article  PubMed  CAS  Google Scholar 

  10. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.

    Article  PubMed  CAS  Google Scholar 

  11. McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718–723.

    Article  PubMed  Google Scholar 

  12. McFarlane SI, Farag A, Sowers J: Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovasc Drug Rev 2003, 21:105–118.

    Article  PubMed  CAS  Google Scholar 

  13. The SOLVD Investigators: Effects of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992, 327:685–691.

    Article  Google Scholar 

  14. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.

    PubMed  CAS  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berecek, K.H., Farag, A., Bahtiyar, G. et al. Clinical trials report. Current Science Inc 6, 211–214 (2004). https://doi.org/10.1007/s11906-004-0071-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-004-0071-z

Keywords

Navigation